Semaglutide and tirzepatide are the two biggest names in this class of medicines. They work in a similar way — both copy gut hormones that curb appetite and steady blood sugar — but there's one core difference, and it's easy to remember.
The one-line difference
Semaglutide pulls one lever; tirzepatide pulls two. Semaglutide switches on a single gut-hormone receptor (GLP-1). Tirzepatide switches on two (GIP *and* GLP-1) with one molecule — which is why it's nicknamed a "twincretin."
Side by side
| Semaglutide | Tirzepatide | |
|---|---|---|
| Receptors hit | GLP-1 only | GIP + GLP-1 (imbalanced toward GIP) |
| Half-life | ~7 days | ~5 days |
| Dosing | Once weekly | Once weekly |
| Brands | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Landmark obesity trial | STEP 1 | SURMOUNT-1 |
Full write-ups: what is semaglutide, what is tirzepatide; the shared biology is in GLP-1 receptor agonists explained.
What the trials actually found
Each has a landmark obesity trial, and in 2025 they were finally tested against each other directly:
| Comparison | Trial | People | Result | Year |
|---|---|---|---|---|
| Semaglutide (alone) | STEP 11 | 1,961 adults | ~14.9% weight loss over 68 weeks | 2021 |
| Tirzepatide (alone) | SURMOUNT-12 | Adults, no diabetes | ~15%–20.9% over 72 weeks | 2022 |
| Head-to-head | SURMOUNT-53 | 751 adults | Tirzepatide 20.2% vs semaglutide 13.7% | 2025 |
In plain terms: the first two rows are separate trials, so they hint but don't settle the question. The third row does settle it more directly — SURMOUNT-5 put the two drugs against each other, and tirzepatide produced more weight loss (20.2% vs 13.7%) over 72 weeks3.
Latest research (2025)
The 2025 SURMOUNT-5 trial is the headline development: the first proper head-to-head, it found tirzepatide out-performed semaglutide for weight loss and waist reduction, with somewhat fewer people stopping for gut side effects3. Two honest caveats keep this in perspective: "more average weight loss in a trial" is not the same as "better for every individual," and semaglutide has its own distinct strength — the SELECT trial proving it reduces cardiovascular events. We update this section as new comparative data reports.
What a comparison can and can't say
The mechanistic difference (one receptor vs two) is a hard fact. SURMOUNT-5 gives a real head-to-head weight-loss answer (tirzepatide ahead). But which medicine suits any individual is a clinical decision, not something a reference page can answer — and the two drugs have different strengths (tirzepatide's weight loss, semaglutide's proven cardiovascular benefit). What we *can* say cleanly: same class, same weekly cadence, one hits one receptor and the other hits two.